Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Tvm Capital Life Science

BioCentury | Jul 22, 2023
Deals

July 21 Quick Takes: Gilead drops CD47 lead indication due to futility 

Plus: Turnstone shares sag after upsized IPO, Idorsia unveils cost-cutting plan, and updates from ADC, the FTC, TVM, Verrica and more 
BioCentury | Feb 9, 2023
Product Development

Feb. 8 Quick Takes: Galapagos slides on Phase III miss for filgotinib in Crohn’s

Plus: CureVac prices upsized $250M follow-on and updates from Novartis, UCB, TVM Capital and more
BioCentury | Feb 2, 2023
Regulation

Feb. 1 Quick Takes: FDA approves GSK’s daprodustat

Plus: Patient Square caps first fund at $3.9B, and updates from Verily-Otsuka Novartis, Evelo, Sherlock-Sense, Recurv and more
BioCentury | May 31, 2018
Product R&D

Lilly’s new leaf

How Lilly’s new R&D head aims to beef up the pharma’s first-in-class cache
BioCentury | Dec 16, 2016
Financial News

AL-S Pharma completes venture round

BioCentury | Jul 28, 2015
Financial News

leon-nanodrugs raises EUR 18.5M in series A

BioCentury | Jun 22, 2015
Finance

Strategic investing in China

The inner workings of TVM's China fund
BioCentury | Apr 20, 2015
Financial News

TVM Capital financial update

Items per page:
1 - 10 of 19